<SEC-DOCUMENT>0001558370-21-007920.txt : 20210602
<SEC-HEADER>0001558370-21-007920.hdr.sgml : 20210602
<ACCEPTANCE-DATETIME>20210602070220
ACCESSION NUMBER:		0001558370-21-007920
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20210602
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210602
DATE AS OF CHANGE:		20210602

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		21987654

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>plx-20210602x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7713.40453 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 6/2/2021 11:02:05 AM -->
      <!-- iXBRL Library version: 1.0.7713.40461 -->
      <!-- iXBRL Service Job ID: cf730505-2444-4b28-91a7-e419188b9d54 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:plx="http://protalix.com/20210602" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:EntityCentralIndexKey" id="Tc_75s5J1SBiU6EJ2qrpIMCnA_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:AmendmentFlag" id="Tc_16cBRw0NhUOhbsBg5x8uHg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="plx-20210602.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_66e6d4a8_9435_4cc8_9e61_2e7ee2b3d21b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:DocumentType" id="Narr_65HSDl5zeEq5CgiLhEU4cA"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of Earliest Event Reported): </b><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_LfKvLgGOR0mr3ZaX-HsRSA"><b style="font-weight:bold;">June&#160;2, 2021</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:EntityRegistrantName" id="Narr_RMPk9AT0NkiR_AcnKa_NnQ"><b style="font-weight:bold;">Protalix BioTherapeutics,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_db44e2d3_a4d8_4690_a9da_b28605fc200d"></a><a id="Tc_EAkA5t6LKkWTchfw8Q0QQA_2_0"></a><a id="Tc_35NZuVms4UWj4gNeE84MKA_2_2"></a><a id="Tc_PQidxox0kEGzZFFDRIx22w_2_4"></a><a id="Tc_jqDE1gnjnE2SFwrW-7TlHQ_6_0"></a><a id="Tc_l23w0ZPdz02eO48OhfowEg_7_0"></a><a id="Tc_9HZcPw9vCEev26Ki26mODQ_7_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_n5SisFktl0KbxQOKiNZv-g_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:EntityFileNumber" id="Tc_vNpMJHenqkuv4-F9kt1IWQ_1_2"><b style="font-weight:bold;">001-33357</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:EntityTaxIdentificationNumber" id="Tc_b3eR1dwvHkyJxXB-Qs_pdg_1_4"><b style="font-weight:bold;">65-0643773</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br /><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer<br />Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:EntityAddressAddressLine1" id="Tc_KkYJED9eREilBmon9Ki_pQ_4_0"><b style="font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:EntityAddressAddressLine2" id="Tc_JskWvg2NfE6LZ24NVb1KXw_5_0"><b style="font-weight:bold;">Suite 100</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:EntityAddressCityOrTown" id="Narr_Ly2fq63HoEuEuqqVUPOC_A"><b style="font-weight:bold;">Hackensack</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:EntityAddressStateOrProvince" id="Narr_w4-wb4wQ40qGAT1oItBe9w"><b style="font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:EntityAddressPostalZipCode" id="Tc_pYQmATRxJ0Om9kmCdQQcPQ_6_4"><b style="font-weight:bold;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">&#160;<b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code </b><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:CityAreaCode" id="Narr_B-pmGgZ3BU67lJz1CIaG2w"><b style="font-weight:bold;">201</b></ix:nonNumeric><b style="font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:LocalPhoneNumber" id="Narr_3GKWUamxTE2TpLP7YTw62w"><b style="font-weight:bold;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report.)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:10pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_zHxlwt26JEO3RYyJss9HgQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_ATvDME1l6k67kvGQ60LWUA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_4B-5ur9dmE-rSu4GkRgdPw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_XGFOyrYucUy4CtPsb6Rs2g"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e77e804a_d223_4729_927d_c6bf13fbe4e3"></a><a id="Tc_U-Q4tsPHxkeKJuFlkr7A9Q_1_0"></a><a id="Tc_dFK2UfSbS0WUb4O2A4DVgQ_1_1"></a><a id="Tc_9K355sRER0Ws-tP6syWTpw_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:Security12bTitle" id="Tc_ewsjgIifb0-sjRAqr20WZQ_2_0">Common stock, $0.001 par value</ix:nonNumeric></p></td><td style="vertical-align:top;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" name="dei:TradingSymbol" id="Tc_5CBPd4ybgUStFTj_YIeZDw_2_1">PLX</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_vhvcfxATR0ajjFMQ4zbYQA_2_2">NYSE American</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_j1lRQXsxmkqGj7YvBxwpww"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;8.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Events</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On June&#160;2, 2021, Protalix BioTherapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), together with its development and commercialization partner, Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., issued a press release providing an update regarding the clinical development of pegunigalsidase alfa<span style="background-color:#ffffff;"> (</span><span style="background-color:#ffffff;">PRX</span>-<span style="background-color:#ffffff;">102)</span> for the proposed treatment of Fabry disease. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<a style="-sec-extract:exhibit;" href="plx-20210602xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press release dated June&#160;2, 2021</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="background-color:#ffffff;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: June&#160;2, 2021</p></td><td colspan="3" style="vertical-align:top;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:40.02%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>plx-20210602xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 6/2/2021 11:02:00 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><img src="plx-20210602xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:39.15pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:128.25pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><img src="plx-20210602xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:47.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:131.85pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:25.9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:25.9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Companies Announce Topline Results from Interim Analysis of<br>Phase&#160;III BALANCE Clinical Trial</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Protalix management to host conference call and live webcast today at 8:30 am EDT</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="background-color:#ffffff;">C</font>ARMIEL, Israel and BOSTON, <font style="background-color:#ffffff;">June&#160;2</font>, 2021 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx<sup style="font-size:9pt;vertical-align:top;">&#174;</sup> plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today provided an update regarding the clinical development of pegunigalsidase alfa<font style="background-color:#ffffff;"> (</font><font style="background-color:#ffffff;">PRX</font>-<font style="background-color:#ffffff;">102)</font> for the proposed treatment of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:25.9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Conference Call</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Protalix will host a conference call today, June 2, 2021, at 8:30 am Eastern Daylight Time, to review regulatory matters related to the development of PRX-102. To participate in the conference call, please dial the following numbers prior to the start of the call:</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:12pt;margin:0pt 0pt 0pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:-0.15pt;">Conference Call Details:</b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Wednesday, June&#160;2, 2021, 8:30&#160;am Eastern Daylight Time (EDT)</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Domestic:</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> 1-877-423-9813</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">International: 1-201-689-8573</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 12pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Conference ID: 13720271</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The conference call will also be webcast live from the Protalix website and will be available via the following links:</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:12pt;margin:0pt 0pt 0pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:-0.15pt;">Webcast Details:</b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Company Link: </font><a name="_Hlt71670855"></a><a name="_Hlt71670856"></a><a name="_Hlt71244620"></a><a name="_Hlt71244621"></a><a name="_Hlt71193847"></a><a name="_Hlt71193848"></a><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">https://protalixbiotherapeutics.gcs-web.com/events0</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;"> </font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Webcast Link: </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </font><a name="_Hlt73057170"></a><a name="_Hlt73057171"></a><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">https://tinyurl.com/42857k4w</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;"> </font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Conference ID: </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">13720271</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Please access the websites at least 15 minutes ahead of the conference to register, download and install any necessary audio software.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">PRX-102 Development Program Update</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">PRX-102 is currently being studied in the pivotal Phase&#160;III BALANCE clinical trial and in two ongoing long-term extension studies, all of which are part of the overall clinical development of PRX-102 for the proposed treatment of Fabry disease. The BALANCE study is a 24-month, randomized, double-blind, active control study </font><font style="background-color:#ffffff;font-size:12pt;">of PRX-102 in Fabry patients with impaired renal function and is </font><font style="font-size:12pt;">designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 dosed every two weeks compared to agalsidase beta (Fabrazyme</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;">). The study enrolled 78 patients who were randomized on a 2:1 scheme.</font> <font style="font-size:12pt;">The BALANCE study is ongoing and assignment to treatment arm remains blinded.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The primary endpoint of the interim analysis is the comparison of mean annualized changes (slope) of the eGFR <sub style="font-size:9pt;vertical-align:sub;">(CKD-EPI)</sub> after completion of at least 12 months of treatment between the two treatment arms. The interim efficacy analysis was conducted on two pre-defined analysis sets: Intention to Treat (ITT), consisting of all randomized patients who received at least one dose (77&#160;patients), considered as the primary analysis for this interim review; and the Per Protocol (PP), consisting of all patients who completed at least 12 months of treatment with no major protocol violations (74 patients). The patient population (ITT analysis set) of the study is comprised of 47 males (61%) and 30 females (39%) with a mean age of 44.3 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The initial top-line results show that the lower boundary of the confidence interval for the mean difference between the two treatments was below the non-inferiority margin pre-specified for this interim analysis in the ITT analysis set and above such limit in the PP analysis set.<font style="direction:rtl;"> </font>At the time of this analysis, two patients discontinued participation due to treatment emergent adverse events (TEAEs). Of these two patients, one discontinued participation due to a related adverse event. No deaths were registered. Overall, safety data appears favorable and consistent with what was observed in previous clinical studies with PRX-102. Unblinded final data is anticipated to be released in the second quarter of 2022 after all remaining patients have completed the 24-month treatment period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Based on the interim analysis of the 12-month data generated from the BALANCE study, and in combination with previously reported positive data from the Phase&#160;III BRIGHT and BRIDGE clinical trials of PRX-102, Protalix and Chiesi intend to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the review of PRX-102 for the proposed treatment of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">&#8220;We look forward to submission of the MAA to EMA for the European Union and to continuing to work with the FDA toward approval in the United States,&#8221; said Dror Bashan, Protalix&#8217;s President and Chief Executive Officer. &#8220;These regulatory milestones are currently our primary focus.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">&#8220;The BALANCE study continues as planned through its 24-month treatment duration to support its final analysis. Based on the entire clinical development program, which includes the BRIGHT and BRIDGE studies, we believe that PRX-102 has the potential to become an important treatment option for both male and female Fabry patients. The BRIGHT and BRIDGE studies have been completed and the studies met the defined endpoints,&#8221; continued Mr. Bashan.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In addition to the BALANCE study, the PRX-102 clinical program currently includes extension studies for patients who completed the BRIDGE, BRIGHT and BALANCE studies, as well as a Phase&#160;I/II clinical trial of PRX-102. Currently, more than 100 patients who participated in such studies continue to be treated in the extension studies, and additional patients completing the BALANCE study are expected to join the extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">&#8220;We thank the patients and clinicians participating in our completed and ongoing clinical studies evaluating PRX-102. As we plan for MAA submission in the EU, we remain committed to advancing our development program for PRX-102 in the United States while also making access to therapy available to eligible patients through our U.S. expanded access program,&#8221; said Giacomo Chiesi, head of Chiesi Global Rare Diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Regarding the regulatory process in the United States, Protalix and Chiesi plan to submit a Type-A meeting request with the FDA to discuss the path for approval of PRX-102.</p><p style="color:#373737;font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">About Pegunigalsidase Alfa (PRX-102)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Pegunigalsidase alfa (PRX-102) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant a-Galactosidase-A enzyme. Protein sub-units are covalently bound via chemical cross-linking using short PEG moieties, resulting in a molecule with unique pharmacokinetic parameters. In clinical studies, PRX-102 has been observed to have a circulatory half-life of approximately 80 hours. Protalix designed PRX-102 to potentially address the continued unmet clinical need in Fabry patients.</p><p style="color:#373737;font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">About Protalix BioTherapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S.&#160;Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix&#8217;s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Protalix&#8217;s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in <font style="color:#373737;">May 2012</font> and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding <font style="color:#373737;">Brazil</font>, where Protalix retains full rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;">Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human a-Galactosidase&#8211;A protein for the treatment of Fabry disease; alidornase alfa or PRX-110, for the treatment of various human respiratory diseases or conditions; PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of refractory gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in <font style="color:#373737;">the United States</font> and outside <font style="color:#373737;">the United States</font>, for the development and commercialization of pegunigalsidase alfa, and with SarcoMed <font style="color:#373737;">USA</font>, Inc. for the worldwide development and commercialization of PRX-110 for use in the </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery.</p><p style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;text-transform:none;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:normal;">About Chiesi Global Rare Diseases</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders. The Global Rare Diseases unit works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available. The unit is also a dedicated partner with global leaders in patient advocacy, research and patient care. For more information visit www.chiesiglobalrarediseases.com.</p><p style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;text-transform:none;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:normal;">About Chiesi Group</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused healthcare group with 85 years of experience in the pharmaceutical industry and a global presence in 29 countries. Chiesi researches, develops, and markets innovative drugs in the respiratory therapeutics, specialist medicine, and rare disease areas. Its R&amp;D organization is headquartered in Parma (Italy), and is integrated with R&amp;D groups in France, the USA, the UK, and Sweden to advance Chiesi&#8217;s pre-clinical, clinical, and registration programs. Chiesi employs nearly 6,000 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Chiesi Group is a certified Benefit corporation. For more information, please visit www.chiesi.com.</p><p style="color:#373737;font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Protalix BioTherapeutics Forward-Looking Statements Disclaimer</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;">To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and &#8220;intend,&#8221; and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among others: risks related to the timing and progress of the preparation of an updated BLA addressing the complete response letter; risks related to the timing, progress and likelihood of final approval by the FDA of a resubmitted BLA for PRX-102 and, if approved, whether the use of PRX-102 will be commercially successful; failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and inability to monitor patients adequately during or after treatment; delays in the approval or potential rejection of any applications we file with the FDA, </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:12pt;margin:0pt;">EMA or other health regulatory authorities, and other risks relating to the review process; risks associated with the novel coronavirus disease, or COVID-19, outbreak, which may adversely impact our business, preclinical studies and clinical trials; risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital; the risk that the results of the clinical trials of our product candidates will not support the applicable claims of safety or efficacy, or that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; risks related to our ability to maintain and manage our relationship with our collaborators, distributors or partners; risks related to the amount and sufficiency of our cash and cash equivalents; risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness; our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial services; delays in our preparation and filing of applications for regulatory approval; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies and institutions; potential product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; and other factors described in our filings with the U.S.&#160;Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.</p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:12pt;margin:0pt;"><b style="color:#373737;font-family:'&amp;quot';font-size:12pt;font-weight:bold;">Protalix BioTherapeutics Investor Contact</b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:12pt;margin:0pt;"><font style="color:#333333;font-family:'&amp;quot';font-size:12pt;letter-spacing:-0.1pt;">Chuck Padala, Managing Director<br>LifeSci Advisors<br>+1-646-627-8390<br></font><font style="font-family:'&amp;quot';font-size:12pt;">chuck@lifesciadvisors.com</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:12pt;margin:0pt;"><b style="color:#373737;font-family:'&amp;quot';font-size:12pt;font-weight:bold;">Chiesi Global Rare Diseases Media Contact</b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#373737;font-family:'&amp;quot';font-size:12pt;">Jenna Urban</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#373737;font-family:'&amp;quot';font-size:12pt;">Berry &amp; Company Public Relations </font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#373737;font-family:'&amp;quot';font-size:12pt;">+1-212-253-8881</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="color:#373737;font-family:'&amp;quot';font-size:12pt;">jurban@berrypr.com</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>plx-20210602xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210602xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !/ 0$# 2(  A$! Q$!_\0
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M'QG_ ,BCJ'_7.@#GOA&RIX)0L< 2MR?PKMYK^T@C,DMQ&B#DDFN#^%=M'=^
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M5BJ^G_\ (-M?^N2_R%3LV 22 !U- '+^*O#2ZA$;VU_=W<8SD<;JK>%O$/\
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M0W)^E8?C."Y1-)NKJ%KJSMY ;N./^+@\_2M33W\-ZWY4MFMN\D7*A059?Y4
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M?G*Y^;=CVS7H-U9VU[%Y5S!',G]UU!%5K+1--TZ7S+2Q@A?^\B &@#0HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>plx-20210602xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210602xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !? 0@# 2(  A$! Q$!_\0
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MUX\26.6))/4FNF\"2W:>(%2W!,3*?-';%=N-HJI2N]T>;EN(=*NDMI:'K1.
M37B_BJ\-[XCNGSE4;8OTKV"^G%M8S3'HB$UX1-(9II)#]YV)KDRN%Y2F>AG5
M2T8P[ZGHWPXL@EA/>,OS2-M!]A7<UB>$[3[)X<M4(P67>?QK;KAQ,^>K*1Z6
M"I^SH1CY!7)ZQX(BUC4GO);R168 ;0HXKK**BG5G3=X.S-:U&G6CRU%=&#X?
M\-0>'4G,<S2F3DEAC%>7>(+K[;KUY-G@R$"O8]5N/LFE7,Y.-B$UX=&KW5RJ
M#EY7Q^9KU,O<IRE5F]3P\V4:<(4*:LMSIH/%,VE:-!IVEJ#+C=))C.">U9\O
MB37@VZ2ZD3/JH%>G:'X?L])L8XQ"IFP"[D9)--\406O_  CUXTL2?+'D''0U
MG'%4?:64+W>YK+ XCV7-*I:RV6QP^A^-]1AOHH;QQ- [!22 ",UZ7=W @L)K
M@'A$+9_"O#M.B,^HVT0ZM(/YUZOXON/L/A>8 \L!&/QXIXVA#VL%%6N++L34
M="I*;NHG ?\ "7:Y+<E$N^&<A1L'3->K+.+335FNI -B9=C7COANU^V>(+*(
MC(W@M]*[/XB:DT%E!I\;$&0Y?'I_D5>+HQE5A2@K$8'$SA0J5ZC;ML9NK_$*
M[EF9--18X@<"1ADG\*QF\0^()3N$\I!]$%6_!-E93ZD\]\T8CA'RJYZFO2Q>
MZ6H $MN /I15G2P\N2%.XJ%*OBX^UG5M?H>4Q>+-<M9.;HY'\+**] \)>)CK
MMNZ3J$N(L;L="/6N;^(,MC*+0VQC:7<=Q3TQ3?AO&QU&Z?\ A"@?SHK0IU,,
MZO+9AAJE6CC%1Y^9?\ Z7Q3XK30D6&%1)=.,A3T4>IKA6\5>(;^4B*5B?[L:
M#BJOB>Z:\\17;L<[6VC\J[;P1+I=MHB;I8A</S)NZYIJG##T%-QNV)UJN+Q+
MIJ?+%')MJ7BE%W,;D#KDH*?8^-]8LYE,L@FC!^96 %>IBZLG&!- <_[0KE)?
MA]I]U/),MY)\[%L*1@?I6<,51E=58)?(UJ8+$0:="HW\SJ;:^2ZTI;U.%:,N
M*\LNO&&LM=S"&ZPAD(0;1TSQ7H&J*FA^$I88V)6*+8I/4YX_K7E&D6YN]6M(
M>NZ1<_G3P-*FU.;5T+,ZU52ITXNS>]CVK2S,=,MVN&W2L@+'ZT5:C3RXD0=%
M4"BO*;N[GN15DD1W5O'=VTD$J@HZD$&O%-<TI]'U2:T<'8#E#ZKVKW&N5\;Z
M%_:6F&YB7-Q -PQW'>NW XCV53E>S/.S/"^VI<T=T5O >N_;;(V$[YFA^[GN
MM=BZ+(A1U#*>"#WKPO3-0FTO48KN'AXVY'K[5W(^)4.!FS?-;8K!3=3FIK1G
M/@<RIJER5G9H[ :38+$T2VL2HW50O!K/U/3M$TS3IKN33[?;&N?N"L#_ (65
M!_SY/6II>O67BZTNK)XBC;<%&[CUKG=&O3]Z:=NIUK$X:K[E-IRZ:'E4TAN+
MEY%0*9&^5%' ]J]8\&Z$-)TI9)5_TB<;F/H.PKF?#OA&5?$<PNT/V>U;*D]'
M->E@8&!71C\2I)4X/0X\JP;BW6J+7I^I@>,KDVWAFZ(."Z[:\AMH_,NH8_[T
MBC]:]8\=0O-X9F* G8=Q^E>21N8W213\RD$?45T9:OW+MW.7.&_K"OM8]ZM8
MA#:11#HB 5-7GEC\1PENB7=J2ZC!9.<U;;XDV8'RVLI/N*\Z6"KW^$]>.8X7
ME7O'2Z_J1TK1Y[M"-Z#Y<^M>>Q>/];DDC0"#<Y ^Y_\ 7JGXB\5W.O*L/EB&
MW4YV@\GZT>#](DU36XWVY@@.]V[9'05WT<+"C1<JRU/+Q&-J8C$*&'D[':^,
M[QX?"0#D>9. IQZD9KA/"5I]L\1VJ$9"DL?RKH_B3<C=9VBG@#>1]*A^&]IY
MFH75T1]Q0H^M*C^[P<I=_P#AAXA>VS",.UO\STJN2^(-WY&@>2#AI7V_AS76
MUYM\2+L/?6MJ#]U2Q'O7!@H<U>)ZF8U.3#2??0Q_!5H+KQ+!D96(%C^1KI?B
M3=8MK6U!Y=BQ'TQ5?X;6N9;NZ([! :R_'UV+CQ$8U.5B0#\:]%_O,:O[J/(C
M^ZRYOK)D_P /+03:U+<$<1)@?7BJ?CFZ-QXEE0GB%=E=1\.;3R])GN".97X/
MTXKB?%"L/$M^'ZF0U5)J>,D^R)K1=/+X+N[E[1_!=YK.GK>1SI&C$@!AG^M7
M_P#A6U__ ,_<7_?/_P!>M3PGXJTJTT:*TNIA#+'UW< ULW'C31((F9;M9&QP
MJ8)-85<1BU4<8K3T.FCA<#*DI3>MM=3DO^%;:@/^7N+_ +Y_^O75>$O#DN@0
MSK/(LCR$<J,<5Y[=^)]6N[^1X;ET65_D0=LUW=_/?Z7X($KRL;O:"S'J"11B
M5B'%0G)>\&#>%4Y5*<7[JWN9.O\ @*YNM0DNK"5")#DHW&#]:PF\"ZXK?ZB,
M^X<4W2_%6I#4K8W=ZWV?>/,X[5Z<FOZ2Z!A?P8(_OTZE7$X=*._R)I4,%BVY
MJ\?F>37OA[5]-B,L\#+&.K*<XJ7P]KE]I^JVZK.[0NX5D8Y!%=IXN\3:?_8\
MUK;7"332C;A#G KA_"^GOJ.OVT:J2L;;W/H*Z*=1U:$I5HV.2K1C0Q,88>5]
MCM_B)=^7HD,(.#,_(_6N7\"6@N?$B.1\L2$_CVJY\1+H2:K!;*>(DR1[\BM#
MX;6O[J[NR/O$*#],UA']U@F^_P"IU3_?9DET7Z'?T445XY]"%(0&!!&0>U+1
M0!YWJOP^N9]2EFLIHDA<[@K9X-4_^%=:G_S\0?K_ (5ZA17;''UDK7/.EE6&
MDV[?B>7_ /"NM3_Y^(/U_P *NZ1X,UC2-3BNX[F$[3\RC/S#TKT.BB6/K25F
M$,KP\)*4;W7F( !S@ GK2T45Q'HC)8DGB:*10R,,$'O7#ZC\.(9IFDL;HQ G
M.QN@KNZ*UI5ZE)W@S"OAJ5=6J*YYB?AOJ(.!=P$?C_A3U^&MZ?O7L(^@/^%>
MET5T?VA7[G)_9.&[?B<#:?#6)7!NKUG _A0=?TKL]/TVUTRV6"UB6-!Z=ZMT
M5A5Q%2K\;.JCA*-'6G&QQOB/P9<ZYJANEO$C0+A5.>/TK5\+^'SX?LI(7E62
M1WW%A6[13EB*DJ?LV]!0PE*-5U4O>85Q6O\ @FZUK5I+P7B(K !5.>/TKM:*
MBE6G2ES0W+KX>%>/+46AB^&M".@Z:;9I%D=FW%A7-ZIX N]1U*XN_MT:^:Q(
M!SP/RKOJ*N&)J0FYIZLSG@J,Z:IR6B,[0],_LC2H;/<&*9RP[\UF>(?!]KKD
MGGAS#< 8WKW^M=)141K3C/G3U-)8>G.G[*2T/-'^&MX#\M["1[@_X4)\-;PG
MYKV$#V!_PKTNBNG^T*_<X_[*PO;\3E-#\#66E3+<3.;B9>F[H*Z.]LX;^SDM
M9ES'(N#5BBN:=:<Y<TGJ=E/#TZ<.2"LCSBY^&LXD8VUZA3/ <<_H*K_\*XU+
M_G[A_,UZ?172LPKKJ<;RK#-WM^)YS!\-)RP-Q?+M[[.OZBNRT;0;+1+?R[9/
MF/WG/4UJ45E5Q56JK2>AT4,%0HOFA'4X?6_ UUJ^K37GVU$#GY5.>!^5=#X<
MT;^P]*6T9P[[BQ8=\UIM/$K;6E0'T+"GJZN,HP8>H.:4\14G!0D]$%/"4:=1
MU(KWF+1116!U%34=0ATVR>YF/"\ #J3V%8\4OB.]C\]!!;(W*QL QQ[YZ4>+
M01;V;M_JDG!D_,8_6M6^N+N.W1["!)R>Q/&*WBDHII:ON<LVY3DFVDK;%:.[
MU&'2KB6]AC2>(?*5.0WO5O2[E[S3+>XD #R+DXK&.K7-[9ZG;7=LL,L"<A3U
MR :JPW=U)9Z5IEI+Y+31Y>7'('/3\JITKIZ6=_PL0JZC)6;:M^-['7UEZ+J$
MVH1W#2@ QR%!CTK/5[S1=7M;>2[>ZMKG(^< %3^'UJCHUC=WWVT)>O;1+,=H
MC ))YZYI*DN5MOMJ.5>3FDEKK='945S=GJ4PL[ZVOKL1R6K[/M '7IS]>:SH
M=2DL]1M!!J,URDT@1TE4#J>HP*2H2=RGBHI)VW.BL;^6XU:^M7 V0,H4CW&:
M;X@O[C3M-,UL%\TNJC=TY(']:KZ5_P C%JW^\G_H(IOB\LNBY5=S"5"!ZG<*
M<8KVL5;L*4Y>PE*^NOYD4DGB:WB,Q%M,%&2@P"1^5;&EZ@FIV"7*#;G(93V(
MX(KG;W7]7A2.W?3EMVG^1)7/RJ35S[+'HV@);R7Q@9B295&22<GBJG"\5=)-
M[6(IU+2?*VTEK?OTW.BHKD--U&2'7(+2.]EN89P<B50"I )XQ4^G#4]2O;EF
MOFBMX+AE554?, >AXJ)4''=FD<4I626NQU%%<0VKMJ%W<&74I+18GV1I&H.<
M=SQ6_P"'=0GO[!C<9+QOLWXQO'K2G0E"-V.GB8U)<J(]=U"^M;FSMK'8'G)!
M+CIC'^-5YK[7M,7S[N"*XMU^^8SAE'K@"I-<_P"0YI/^\W]*VKN2..TE>8@(
M%.<U5U&,5RWO_F2XRE.;YFK?=L5'UB 6EM<QI)+'.0%*+G'UK1KB+&XN;3P_
MI[1L462?C(S\M6-5NKI-8E2\NI[2U 'E/&H*GUSG\*;H:V7F3'%6CS27;\4=
M?17*:MJ[VT-C:0WIVS\M<XYV^P]:;INIR0:M%;1WDEY;R@[BZX*$#.>E3["7
M+S%_6H<W+_6IUM%<9J5ZJM<W%OK,YDCR514&T$=NE3:AJ6H3Z987"&2."0?O
MY(@"P_.CZO+37</K<5?38ZVBN635%L=!N;N"_:\*D >8 "A) K-_M2:VBBNX
M]4EN+@D%X2@VD=P.*:P\F*6,A&U_7H=W17(:K>W?]HH;F>>TLFC#(\2@C) Z
MY_&NCTME>PB9+K[2I'$I'WJB=)QBI=S6G64Y.*6Q<K!U;4;F:]&F:>P64C=-
M*?\ EFO^/2MZN0MV8V.NW(YFWX]\ 4Z,4VVR<1)I**Z_H<WK-Q:6-PKQ7$\L
MJ9&6D)\PGCIZ5L^&X-;M]$:[BD#R,^_R'.<KZ#TKG](L@R?VC=9>:0YC7&=H
M]:VH=8FL-;L+<.Q,K$2*>P.,&O2JKW?9QU:WOY'C4))3]K/1/:WGU.STO4HM
M3M!-'E6!VNAZJWI1698@6WBJ[ACXCFC\TJ/48%%>74BD]-CW*,G*/O;K0VKJ
MUBO+9X)T#1N,$&L1-#U2T7RK+5"L X59025'H,5T-%*-2459#G2C-W>YBVV@
MF*WNA+<O+<7(P\C4V7P_NLK1(;@QW5J,)*/ZUN44_:SO>Y/L*=K6,6TT6X^W
M)>:C=?:)(P1&JC"KGO5>/P_>V;3/8W_EF9RSA@2*Z*BG[:8OJ],P#X90Z5);
M&=C/(XE:8]2W'^%-.@7=Q-;RWMZ)&@D#J$& <&NAHH]M/N'U:GV*%IIWV;4;
MN[WY^T$';Z8&*-6T[^T[00;]F'5L_0@_TJ_14<\K\W4T]G'E<>C*E_I\.H6+
MVLPRK#@]P?6LV?09YK&UC-V3<VS;HY3^.,UNT4XU)1V%.E"6K1A0:%<?VC;W
MUU=^;+%GA1A<$8J]ING?8/M'S[O-E:3Z9.:OT42J2EHQ1HPB[HP)-"N8+J6;
M3;M84E.7C=<C/J*U;"WFMK8)/,9I.I:K5%$JDI*S'"E&#NC(UG2)M1EMIK>Y
M\B6 D@X]?_U55;P]=WA"ZEJ4DT&<F)> WUKH:*:JS2LB98>$I-OJ9E_I"7<-
MM%&PB2!PP J"_P!,U.YFE$5^BP2#&QE)(^E;5%)5)(<J,)&%)X;C^P6T4$S1
MSVYW1R^YZ_AS4MIIFH+*QO+U9(RI78BXZUL44W5DU9B5""=TCFD\-W<=O+9I
M?!;-]WR@?-SVS5LZ1>P65O;V5Z(_*&#N&0U;5%-UIO<2P]-;?F85MX<0078O
M)?-EN>78< >F*;!HVJ0^7%_:2F!",?+\Q'IFM^BCVT^H?5Z>EC'O=.U.:<FW
MOD2(C&QU)Q]*M:3IJ:78I;(Q;')8]S5ZBI<VX\O0M4HJ7-U"N:N#_8NL2R3(
M3I][]\@<(W3GVKI:9+#'/$T<J*Z-P589!HA/E>NP5:?.M-T<%XBN[/1HH+:Q
M_>SL/W2@Y 4^M4O#VD.;QM3U"0#9\[NQX'L*Z>\\&VL^H+=PR&(A"FW&0.O3
M\Z6R\(QPJD=U=RW,2'(C)(4GW'>NY8BFJ?*GJ]^YY;PM65;FE'1;=B704>]O
FKK570JDAV0@]=HX_I16\B+&@1%"J!@ =J*X9RYG<]2G#DC8__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>plx-20210602.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 6/2/2021 11:02:08 AM-->
<!--Modified on: 6/2/2021 11:02:08 AM-->
<xsd:schema targetNamespace="http://protalix.com/20210602" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:plx="http://protalix.com/20210602">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210602_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210602_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>plx-20210602_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 6/2/2021 11:02:08 AM-->
<!--Modified on: 6/2/2021 11:02:08 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="plx-20210602.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="plx_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>plx-20210602_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 6/2/2021 11:02:08 AM-->
<!--Modified on: 6/2/2021 11:02:08 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="plx-20210602.xsd#DocumentDocumentAndEntityInformation" roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="plx-20210602.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637582285287218798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_637582285287218798" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637582285287218798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_637582285287218798" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637582285287218798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_637582285287218798" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637582285287218798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_637582285287218798" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637582285287218798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637582285287218798" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637582285287218798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637582285287218798" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637582285287218798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_637582285287218798" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637582285287218798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_637582285287218798" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637582285287218798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_637582285287218798" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637582285287218798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_637582285287218798" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637582285287228762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_637582285287228762" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637582285287228762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_637582285287228762" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637582285287228762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_637582285287228762" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637582285287228762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_637582285287228762" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637582285287228762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_637582285287228762" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637582285287228762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_637582285287228762" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637582285287228762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637582285287228762" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637582285287228762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_637582285287228762" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637582285287238814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_637582285287238814" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637582285287238814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_637582285287238814" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637582285287238814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637582285287238814" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637582285287238814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_637582285287238814" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637582285287238814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_637582285287238814" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>plx-20210602x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20210602.xsd" xlink:type="simple"/>
    <context id="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Tc_75s5J1SBiU6EJ2qrpIMCnA_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Tc_16cBRw0NhUOhbsBg5x8uHg_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Narr_65HSDl5zeEq5CgiLhEU4cA">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Narr_LfKvLgGOR0mr3ZaX-HsRSA">2021-06-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Narr_RMPk9AT0NkiR_AcnKa_NnQ">Protalix BioTherapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Tc_n5SisFktl0KbxQOKiNZv-g_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Tc_vNpMJHenqkuv4-F9kt1IWQ_1_2">001-33357</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Tc_b3eR1dwvHkyJxXB-Qs_pdg_1_4">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Tc_KkYJED9eREilBmon9Ki_pQ_4_0">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Tc_JskWvg2NfE6LZ24NVb1KXw_5_0">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Narr_Ly2fq63HoEuEuqqVUPOC_A">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Narr_w4-wb4wQ40qGAT1oItBe9w">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Tc_pYQmATRxJ0Om9kmCdQQcPQ_6_4">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Narr_B-pmGgZ3BU67lJz1CIaG2w">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Narr_3GKWUamxTE2TpLP7YTw62w">696-9345</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Narr_zHxlwt26JEO3RYyJss9HgQ">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Narr_ATvDME1l6k67kvGQ60LWUA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Narr_4B-5ur9dmE-rSu4GkRgdPw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Narr_XGFOyrYucUy4CtPsb6Rs2g">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Tc_ewsjgIifb0-sjRAqr20WZQ_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Tc_5CBPd4ybgUStFTj_YIeZDw_2_1">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Tc_vhvcfxATR0ajjFMQ4zbYQA_2_2">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A"
      id="Narr_j1lRQXsxmkqGj7YvBxwpww">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140397822701720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  02,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " !).,)299!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 23C"4IE<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " !).,)2.7XZ6UD$   *$0  &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 23C"4I^@&_"Q @
MX@P   T              ( !G P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" !).,)2EXJ[',     3 @  "P              @ %X#P  7W)E;',O+G)E
M;'-02P$"% ,4    " !).,)2'#AEZC\!   \ @  #P              @ %A
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 23C"4B0>FZ*M    ^ $
M !H              ( !S1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ 23C"4F60>9(9 0  SP,  !,              ( !LA(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="plx-20210602x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="plx-20210602x8k.htm">plx-20210602x8k.htm</File>
    <File>plx-20210602.xsd</File>
    <File>plx-20210602_lab.xml</File>
    <File>plx-20210602_pre.xml</File>
    <File>plx-20210602xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20210602x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "plx-20210602x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20210602_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20210602_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20210602.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plx",
   "nsuri": "http://protalix.com/20210602",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210602x8k.htm",
      "contextRef": "Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210602x8k.htm",
      "contextRef": "Duration_6_2_2021_To_6_2_2021_C0fgCdY0Ik-psZfy0Tgn0A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "plx_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://protalix.com/20210602",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-21-007920-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-007920-xbrl.zip
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M3JM<G-A6J0&S=KY"CB(9+=[]678F9M0A_WLR!V.%-@)1'_G[5BS4$6S;[MK
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M(-7^P/2P1>R!:TZ0"^UWVQ/_\? !6P75"M(,[*#>V#(XX"M3%VL2W6O;)E#
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MU5JPYV#E03'8.9\GN &&LZ*X@V!/):P&Y+L$**> Z2DOX%G#"-NA7*AE8]1
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MX07>&"M#?J.52E0[GG$4]PS+VZ[X#4/D6@2Q&,F,ZK#N22,*,Z!^D(R6!F)
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M#5L$,5V!">&O&Z'FYZ-<]P9)S=Q&/W$=J?<PQ[UK^?SIM)J=[)Q?PI?8.A]
M];KT.H 0']/]D6#\STHP;L8'"SJ*0&ZC^5FP/K5M!O4#/)ZIPM:]R0-C/1>D
M& P@%:SS,DDA9,2BB RUO5;I/5NV"12ZR0S"(+PH\,R6GG^!?V2O(:+XBI"#
MO&2!WV8$94@'F<K$%S4NNL$S>)DG5:!R3Y[G![14;5[_?9_6L?'*\J<BT"XT
M/^^PX,(Q>!2A+I')_6Z_:\LF=6#C/QU!UY<:)!OM&FB&-*X%'X-07/. ?@79
M(.5U19>UJZ9U8NW0V")SDO#0?1%PP878Q5/LK3,?&ELH)@Q$UY%P"5&>$V*H
M\&>IV=A.#)$_%2DQQ:QMNB"#.(:JAQA#+)>4*,V8"Y5#= #RC&_0BOS>W/<Y
M4M0_ZC-5J<T,>)4"LF0+?2U5KM(2A/:.;,,$)P<"QUBH=IT:X$7M=&[U8)&0
ME-0OX3J6>#Q5V$/66F24OXU?^&BS-[ *RLK+##7$4A9[W8'LLUD[(O+:.7!C
M?E]X@N;_O?JBS#RKOK[V@>\5(B!P^H"4@%WK8)%/USWVTRUC4@B2D*-]VT6&
M4HCE#8#YM@/+IF 7<;H+?&UC+O?29<-I^U+_N!FON;7ZI:#$.TO@_($#_DUM
MBG4YKC+-3:=4+"1]J'L+@ U$MJGKP;!#-C4,$X4<LW0PQ?5?>)H/ST&QQCSS
M> @(A^EYU]O3(#?;)G+OM'P_,Q)WK.OO"?OAB)2TWC<:/T)LRW$ UMP/_[0C
M?)J)6&1U:<,;UBH&PXXTGYUKL?HGVA+U3SG#YFH.-75%FB=J;L ,<9W,V4&K
MB]4S,CW?-<9\V-.0E)%KB;!MEH*RUR(3(XE9))T[6[W>SE0?/%FV-VNLRPM)
M5&Y*4>+^L)TE>*<4Y:,IF+!F'9Q9E'!8DGZV?,"-JNN8A0W93;U TD1) FJ,
M;XZC##PB0$R#19B#AT= 2YW,@F=U%=IJ&'S!M0X%B26#*\1JS)]!])*7VI3<
M=::[,P !V)_0MN.B&+BT@SW*+Z=X6N"3B$J7,7HG?:V"70N4(W8:$=SH'1_O
M6Z^)QSV,[_*QU=RJ>.>NU@V!RW=<T\GR92R1I&L>AS7_LF;\E,]7GH0P>_D:
M?I5@Y9HJDWCYHIG@57\1*>INV#ZW5O..A=_X35G*+.03;9,,(V8 =B1<NR89
M8HI]W^;7J'5*CN;++&QPF AL5IB\+ .F#)$J..AMIF:V(:S,[,]:FEOCKJ#)
MX+ &*5P:"0@'L*2D,XU%24=.,(G9]%K66-J68RHF8L,P?HY):%L;J;H*&ZM"
MX?.+7UILZ#N9J!QN.Q5L[]'(+M.*D.L/Y\96/$'PW=( 3V#W$="&,N+444N'
M5)8QL<RF*J&ZT 24%FZ-M:!J$%*DZB&RC59^@Y1!7^JL0!J%HNJ4+FP[A>TW
M% @M74R681QGJA3"XBA@CRDAY.E.'_NQE/>D;/1B&]]8 NJ<8FK(YG8&CIE+
MW\ J< WV+ HY,K0I3J-AA5A9JPY,^"_'@<]X=^JK6M7WXUQO B$$(#X 9SI<
M/+QOVE8]I_V XRW09()%"YC/=;'Y^D0CU4V$1JJ'KD$!U]/L/Z#<MAQ5>7)*
M_Y*JX1!(MT8#J/_<2)V< ;D$H<$".\0D0S8"G$_"@^6(A,_K#X+!"T!P&V4L
MGR^QC8ABI3NC;O2H.F1]OYT3%N(LY?:-H.9L-K+L;Z1C!\S8IGV2IZH-1E.G
M!6:X7-@ "]"EI(AE"#H,1 *M MSCFKVE,26F &.LGJ:^(QC>Q[0!!E7N?L*C
M6P*D(&1TMHVBMKC4"PTH=C=#6*6-VN9(E3)# L-SF1,M0H>$77TQ&R7;'V"6
M15GA96K5#15'ZPAR8[//5O4;755T+,2E,>N9X7D0?EDT&ZG KOQ:VC*N6SKV
M,E#;>!77#2V/*\!;U\=THX]1BU_LJ0&?LN%U8S)UVHRDKUD[H6W]D=#[#TOH
M/?CQ &RZ!JFQ/MX&>QMJ:PNYN-I<NF;L1M^ZZ_OQ1I4;H\!@53&0/6 #7@S1
M/"C15.K2^-BKA8LY^_@_E^<!%A/ %1)SF\;'G1K!WL0TYXC50-=\%JKU6'.V
MQN13>1H3 [9,02J"$UI[4@6W90A*1)KFP"3HJSLD1%$I?ON PVXP,82?"2:K
M@,652'@/OS'+16=R';7M.8G$]1W65?&I!2^9<1O##!-9.#O=T+("$4!U=*KA
M_%<=MZD=P7*YS+H=0NRN<]M9&S0CV/1&08B%@M96 UG\.4-B)2WAH<$IA67K
M(H8.!UN*$]JLOK.U)$7XMSO@8?OG-[",T7C'RFB951X'__P-D!94!K^ZMX[W
MN,2F548,R67FT@T9'9\K70X:96,B72;$MCSZ'"+YOQ@9)<.27 :9=LJMK9N6
MR)EBZH-F,B723M*1$,>4B)N)2S/"#RAJMH%I<32GA"N[N!5T%#@N$\KQS2U(
MK: 3>&J(6;"M@KY)FA-LP)0&'<MD]K.@6GCIQ>&Q E9P0H+(.UMLI'PD$1VC
MQ;"@ST/""FT;9HX! ;V?X>$EBM7I.!Z"):EM\K'Z^J]-*F'GD_095A2^A'2B
MKO0B\3'Q1IE/%_HOP5H_1M-;.L!3049*/\O$'P1M.DC*,3<LH?.Q0W?4:6*A
M\J;@ ^9JM(5@>@KKH@5NWG@@BPI1<:.8Y_BQ%8H@ZC?=;,[0C993XHCFJM9C
M#0; 4JR#G!/1) -W/,9KX;QJB_"??E_",D"E&CEX94VDER;:ILLKT8Z)1Y$%
M*!ZR )J&U?G:_]((M?.H/_L"\Y>4_V(4X8"6-2-.!RC1*D2@3S;/A@RT##.U
M.ZF;B1J!/0YT<6</;+,S[!.FAAY_L/X1J8HIUN9!:K$]KN(3?98:F4^@*D:6
MQ2X;8_4 W,.X.O'B/F/MSHDVTE3B+A)Y@>,Z0(V]K=)UUR1\UGZI'QL*'Y$^
MHRSGKZ4J'O45DDWYKTO"WH@'X"60A>?[.."7?8+)$X;^>2QAUGSERF5%2XAJ
MKGC,$]YB[]$5H<J=TXE@I?'O,;R3(_$IDNPTGF+YR^"U_^X%!WL'P4'_,#C:
M/>[BI0>_C[5Y<5LG$2[C[]AM:L +NXDPI_K"/XWUY-)Z7ST4CW7RYY?6AR7S
MBXBP=?(/D66<?=8ASU[(Y^:>:&.OA08O1$\P_PW.*XOOKSW2>RE?V'NB+8-A
MZ/?Z07]_-S@Z.EK_9;NGW,.C_]+75^[GEQ+%\N\A<C+7RQ;I1V4ROCUM,54R
M?BAKT;%_GY/^X.?)_P%02P$"% ,4    " !).,)2)DPZ+K$#  ###   $
M            @ $     <&QX+3(P,C$P-C R+GAS9%!+ 0(4 Q0    ( $DX
MPE(<>E,#IP4  &\_   4              "  =\#  !P;'@M,C R,3 V,#)?
M;&%B+GAM;%!+ 0(4 Q0    ( $DXPE* %'-PG 0  - J   4
M  "  ;@)  !P;'@M,C R,3 V,#)?<')E+GAM;%!+ 0(4 Q0    ( $DXPE*G
M%\7XZA,  />0   3              "  88.  !P;'@M,C R,3 V,#)X.&LN
M:'1M4$L! A0#%     @ 23C"4CU <)!3'   PW0  !<              ( !
MH2(  '!L>"TR,#(Q,#8P,GAE>#DY9#$N:'1M4$L%!@     %  4 2 $  "D_
$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
